European Medicines Agency Management Board Elects Kent Woods as New Chair
At its June 9, 2011 meeting in London, the European Medicines Agency’s (EMA) Management Board unanimously elected Kent Woods, Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom, as chair for a three-year mandate.
Accepting his election, Professor Woods told the Board that, “it is my ambition to provide strategic leadership in helping the Agency to continue to protect public and animal health and maintain public trust.”
Proposals for better handling of conflicts of interests
The Board agreed on a way forward for introducing changes to the way the Agency handles potential conflicts of interests of staff members. The proposed changes are aimed at achieving a more robust system for staff, mirroring the same principles on handling conflicts of interest adopted by the Board in October 2010 for committee members and European experts.
Once implemented, the rules will clarify allowable and non-allowable interests for staff, and strengthen controls on the appointment of individuals as product team leaders. The rules will also require new Agency recruits to divest any interests prior to appointment.
The Agency also initiated discussions with the Board to find a common approach for the management of conflicts of interests throughout the EU network.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
